Drug profile · INN
dantrolene sodium, hemiheptahydrate
AGILUS
dantrolene sodium, hemiheptahydrate (AGILUS) is a ryanodine receptor 1 antagonist.
EMA: approved Musculo-skeletal system (M03) M03CA01
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dantrolene sodium, hemiheptahydrate
- Class
- Musculo-skeletal system (M03)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
dantrolene sodium, hemiheptahydrate (AGILUS) is a ryanodine receptor 1 antagonist.
Key facts
INN dantrolene sodium, hemiheptahydrate
Brand AGILUS
Mechanism Ryanodine receptor 1 antagonist
Target Ryanodine receptor 1
Therapeutic class Musculo-skeletal system (M03)
ATC code M03CA01
Mechanism of action
Ryanodine receptor 1 antagonist
Primary target: Ryanodine receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dantrolene sodium, hemiheptahydrate?
dantrolene sodium, hemiheptahydrate (AGILUS) is a ryanodine receptor 1 antagonist.
What is the brand name for dantrolene sodium, hemiheptahydrate?
AGILUS is a marketed brand name for dantrolene sodium, hemiheptahydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.